We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.58 | 1.43 | 0.66 | 0.71 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 16.48 | 10.99 | 3.70 | 1.89 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 359 | 306 | 306 | 147 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.59 | 0.84 | 0.09 | 0.29 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 211.04 | 257.24 | 26.39 | 42.17 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 66.79% | 38.19% | 66.93% | 67.24% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (291.75) | (238.27) | (215.39) | (183.12) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (138.24%) | (92.62%) | (816.23%) | (434.23%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (291.75) | (237.89) | 28.51 | 168.02 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.70 | 3.79 | 5.28 | 3.92 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.72 | 2.73 | 0.23 | 0.36 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | (3.76) | (2.53) | 0.25 | 1.43 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.11) | (1.86) | (0.18) | (1.18) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.03) | 0.00 | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.13) | (1.86) | (0.18) | (1.18) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (1.77) | (2.05) | (1.15) | 0.52 | ‡‡‡‡ | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 77.63 | 94.16 | 114.55 | 117.14 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | ‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 5.11 | 0.97 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.13 | 1.15 | 5.99 | 3.94 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 0.00 | 0.00 | 2.73 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.47 | 2.55 | 17.89 | 4.89 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.88) | (3.73) | (22.08) | (1.48) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (241.12) | (174.88) | (20.44) | (138.51) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.04) | (0.29) | — | — | ‡‡‡‡‡ | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (243.16) | (175.17) | (20.44) | (138.51) | ‡‡‡‡‡ | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 242.54 | 143.86 | 58.60 | 66.32 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 475.38 | 473.37 | 264.93 | 37.05 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 283.70 | 355.62 | 138.94 | (135.07) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (137.42) | (193.42) | (131.99) | 61.01 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (50.29%) | (42.85%) | 5.29% | 47.54% | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (109.76%) | (78.30%) | (1,795.44%) | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,470.09% | 143.81% | (17.52%) | (473.47%) | — | — | — |
ROE
|
Analyst Commentary (Summary)
Coherus Oncology, Inc. (CHRS) Latest News
12 Aug
Coherus Oncology (CHRS) released Q2 2026 earnings results and held an earnings call discussing financial performance and outlook. Earnings call delivers financial results and forward guidance that can materially shift investor views and stock trajectory.
6 Aug
Coherus Oncology, Inc. released its Q2 2026 earnings call summary covering financial results and outlook. Earnings call results and guidance can moderately shift near-term investor views and trading.
Coherus Oncology Inc reported Q2 2026 earnings call highlights focused on LOQTORZI growth and pipeline progress. LOQTORZI growth and pipeline updates point to moderate revenue and development effects on future performance.
5 Aug
Coherus Oncology Q2 earnings call highlights cover quarterly financial results, operational updates, and forward guidance for CHRS. Q2 earnings call directly reveals performance metrics and strategy shifts that move investor sentiment and stock trajectory.
Coherus Oncology reported a Q2 loss and missed revenue estimates. Q2 loss and revenue miss signals weaker financial performance likely to pressure near-term stock valuation.
Coherus Oncology reported second quarter 2026 financial results and issued a business update. Quarterly earnings and business updates supply performance data that can shift near-term valuation and sentiment.
23 Jun
Coherus Oncology and Zumutor Biologics announce clinical collaboration to evaluate ZM008 combined with LOQTORZI (toripalimab-tpzi). New collaboration adds clinical evaluation of ZM008 plus LOQTORZI to Coherus oncology pipeline.
14 May
Analysts downgraded Coherus Oncology, Inc. (NASDAQ:CHRS) today, highlighting key concerns for investors regarding the company's outlook. Analyst downgrade signals moderately noticeable pressure on CHRS stock price and investor sentiment.
12 May
Coherus Oncology, Inc. released Q1 2026 earnings call summary highlighting financial results, operational progress, pipeline developments, and forward guidance. Quarterly earnings summaries reveal financial health and strategic updates that significantly sway stock performance and investor confidence.
Coherus Oncology Inc (CHRS) Q1 2026 earnings call highlights strong LOQTORZI sales growth amid ongoing developments. Strong sales growth of key product LOQTORZI likely boosts financial performance and investor sentiment significantly.
11 May
Coherus Oncology reported Q1 earnings call highlights, covering financial results, revenue from biosimilars like Udenyca, pipeline updates, and forward-looking guidance amid competitive oncology landscape. Q1 earnings highlights detail financial performance, product sales, and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.
Coherus Oncology, Inc. (CHRS) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates directly impact financial performance, pipeline progress, and investor sentiment for a biotech company.
1 Apr
Coherus Oncology (CHRS) investment narrative shifting amid revised growth assumptions and elevated execution risks. Changes in growth assumptions and execution risks could significantly alter CHRS's strategic trajectory and investor sentiment.
25 Mar
Coherus Oncology (CHRS) upgraded to Buy rating by analysts, driven by strong clinical data for LOQTORZI, promising revenue growth from UJULTA launch, and undervalued stock position amid oncology portfolio expansion. Analyst upgrade to Buy highlights strong product momentum and undervaluation, likely driving significant stock gains and investor interest.
14 Mar
Coherus Oncology pivots to immuno-oncology focus, reports strong LOQTORZI sales growth, and unveils new pipeline developments at Citizens Conference. Strategic pivot to immuno-oncology with LOQTORZI growth and new pipeline constitutes major shift in company trajectory and investor outlook.
9 Mar
Coherus Oncology Inc (CHRS) reported strong revenue growth in Q4 2025 earnings call highlights, alongside key operational advancements boosting financial outlook. Strong Q4 2025 revenue growth represents a major strategic financial milestone likely to enhance CHRS's market performance and investor confidence.
Coherus Oncology, Inc. (CHRS) released Q4 earnings call highlights covering financial results, operational updates, pipeline progress, and strategic outlook. Q4 earnings call highlights reveal financial performance, guidance, and pipeline advancements that significantly shape CHRS investor sentiment and trajectory.
Coherus Oncology, Inc. (CHRS) released Q4 earnings snapshot reporting financial results. Q4 earnings snapshots reveal key financial metrics that significantly influence stock price and future market trajectory.
Coherus Oncology, Inc. (CHRS) reported full-year and fourth-quarter 2025 financial results and provided a business update. Earnings reports and business updates significantly impact financial performance, stock price, and investor sentiment.
Coherus Oncology (CHRS) reported a Q4 net loss and revenue below analyst estimates. Q4 loss and revenue miss signal weaker financial results, likely affecting short-term investor sentiment and stock performance.
8 Mar
Coherus Oncology announced a 90% debt reduction, surging LOQTORZI sales, and key 2026 data catalysts. 90% debt cut improves financial health, LOQTORZI sales surge drives revenue, and 2026 catalysts offer growth potential.
5 Mar
Coherus Oncology (CHRS) narrative evolves around upcoming clinical catalysts offering potential upside amid persistent valuation risks that could pressure stock performance. Clinical catalysts represent major milestones that could significantly alter CHRS trajectory, balanced against valuation risks impacting investor sentiment.
18 Feb
Recent developments are rewriting the story for Coherus Oncology (CHRS), signaling positive shifts in its strategic outlook and market narrative. Recent developments represent major strategic moves likely to significantly alter CHRS's trajectory and investor sentiment.
17 Feb
Coherus Oncology, Inc. closed its underwritten public offering of 16.67 million shares of common stock at $6.00 per share, generating gross proceeds of approximately $100 million before expenses, with net proceeds intended for general corporate purposes including commercialization and clinical development. Closing the public offering injects substantial capital essential for funding oncology drug development and commercialization amid biotech funding challenges.
12 Feb
Coherus Oncology, Inc. has announced the pricing of its public offering of common stock, aiming to raise capital for general corporate purposes. The offering consists of a specified number of shares at a set price, with underwriters granted a 30-day option to purchase additional shares. The transaction is expected to close shortly, subject to customary closing conditions. The public offering may provide necessary capital for operations but does not fundamentally alter the company's strategic direction.
Coherus Oncology, Inc. has announced a proposed public offering of its common stock. The company intends to use the proceeds from the offering for general corporate purposes, which may include funding research and development, working capital, and other operational expenses. The offering is subject to market conditions and other factors. The public offering may influence the company's financial performance and market sentiment but is not expected to fundamentally alter its trajectory.
25 Jan
Coherus Oncology, Inc. (CHRS) shares surged by 28.7% following a successful at-the-market (ATM) offering and positive analyst coverage. The offering is expected to bolster the company's financial position, enabling further investment in its pipeline. Analysts have expressed optimism about Coherus' future prospects, contributing to the stock's upward momentum. The ATM offering and bullish analyst coverage are likely to significantly enhance Coherus' financial stability and market perception.
12 Jan
Coherus Oncology, Inc. (CHRS) is highlighted as a promising penny stock for January 2026, with potential for significant growth due to its innovative therapies and strategic partnerships. The company is focusing on expanding its product pipeline and enhancing its market presence, which could attract investor interest and improve its financial outlook. Analysts suggest that CHRS may benefit from upcoming clinical trial results and regulatory approvals, positioning it favorably in the competitive oncology landscape. Upcoming clinical trials and potential regulatory approvals could significantly impact Coherus Oncology's market position and investor sentiment.
6 Jan
Coherus Oncology, Inc. (CHRS) management is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference. This event is a significant platform for the company to discuss its strategic initiatives and future plans with investors and industry stakeholders. Participation in a major healthcare conference can enhance visibility and investor sentiment, potentially influencing market performance.
5 Jan
Coherus Oncology, Inc. announced the publication of research in Molecular Cancer Therapeutics that highlights the strong pharmacological properties of its investigational CCR8 antibody, Tagmokitug (CHS-114). The study demonstrates the potential of Tagmokitug in targeting CCR8, which is implicated in various cancers, suggesting promising therapeutic applications in oncology. The publication of strong pharmacology data for Tagmokitug could significantly enhance Coherus's competitive positioning and investor sentiment in the oncology market.
Coherus Oncology (CHRS) exemplifies biotech’s high-stakes volatility, where biosimilar launches like Udenyca and Yusimry have driven revenue peaks—$476 million in 2020—followed by steep declines amid competition, now trading at deeply depressed levels in early 2026 with negative book value and heavy dilution. Despite profitability swings, eroding margins, persistent cash burns, and a precarious balance sheet (net debt up sharply, equity negative), analysts forecast 150-500% upside, fueled by a projected 2025 revenue cliff to $43 million giving way to recoveries toward $119 million by 2027, alongside toripalimab partnerships potentially tapping PD-1 markets.
Historical patterns show stock prices tightly correlated with revenue inflections (r=0.78), from $32 highs on early hype to $0.66 lows amid dilution traps, yet current 0.6x P/S and 1.8x EV/Sales scream oversold relative to peers and past cycles. Insider silence (no buys) tempers optimism, but forward EBT surges, ROA positivity, and FCF rebounds signal re-rating potential if efficiency stabilizes—Monte Carlo models peg 35% odds of targets hitting, with asymmetry favoring tactical longs on dips below 1x P/S.
This risk-reward skew echoes classic biotech turnarounds, where patient capital weathers 40% drawdown risks for 3-6x rewards, but demands vigilance on debt, shares ballooning to 149 million, and execution hurdles like patent battles.